Objectives: The Tack implant is designed for focal, minimal metal management of dissections. This study evaluated Tacks for treating postpercutaneous transluminal angioplasty (PTA) dissection in patients with below-the-knee (BTK) arterial occlusive disease.
hospitalization, fewer major complications, and better patient acceptance have made PTA a reasonable treatment choice for many patients with CLI [4, 5] . PTA depends upon mechanical dilatation of the artery and is associated with plaque fracture, intimal splitting and localized medial dissection. Localized post-PTA dissection is a common and expected adverse outcome associated with the angioplasty mechanism.
The traditional approach to treating post-PTA dissection has been stent placement. In the SFA, stents acutely improve outcomes, but they have also been shown to induce chronic injury and inflammation leading to high 1-year restenosis rates ranging from 20% to 37% [6] [7] [8] [9] . After BTK stenting, immediate technical and procedural success appear high, but so are the complication rates for clinically driven target lesion revascularization (CD-TLR) and amputation. Reported rates of CD-TLR are as high as 34% for bare metal stents and 30.5% for drug-eluting stents at 12 months [10, 11] . Amputation rates range from 10.4 to 20% and 6.4 to 13.8% after placement of bare metal or drug-eluting stents, respectively [12, 13] .
The minimal-metal Tack® implant, is designed for focal treatment of post-PTA dissections with low outward force and reduced metal burden compared to stents, to reduce the likelihood of inflammation and intimal hyperplasia. In previous studies, including a multicenter investigation of 130 patients, Tack implants have been shown to be effective in treating post-PTA femoropopliteal dissections [14] .
Herein we report the first, prospective, multicenter study evaluating the safety and efficacy of the Tack Endovascular System ® for treating post-PTA dissections in the BTK arteries.
| M A TE RI A L S A ND M E TH ODS
The TOBA-BTK (Tack Optimized Balloon Angioplasty Below the Knee) Study was an early phase prospective, first-in-human, single-arm, multicenter, open-label, nonrandomized study. The study was conducted in accordance with the Declaration of Helsinki. The local ethics committees at the participating sites approved the study protocol and all patients provided written informed consent prior to undergoing any study procedures. Patients that provided informed consent and met the study entrance criteria were considered enrolled.
The objectives of this study were to evaluate the safety and performance of the Tack Endovascular System for the treatment of dissections resulting from PTA of BTK lesions.
| Patients
A sample size of 35 was prespecified to ensure there would be at least 30 subjects followed for 12 months. In terms of safety assessments, a sample size of 35 provided an 80% chance to see at least one significant safety event if 4.5% or higher of subjects experienced the event.
Patients were selected based on clinical and angiographic criteria as listed in Table 1 . Patients were eligible for the study if they had the following: CLI; Rutherford Category (RC) score 4 or 5; reference vessel diameter BTK between 1.5 and 4.5 mm; lesion located in the arteries between the knee joint and the ankle; de novo target lesions with >70% stenosis; 1 or 2 tibial arteries requiring treatment with a total treated segment 15 cm; and angiographic evidence of a post-PTA dissection. Major exclusion criteria included: presence of extensive forefoot gangrene/ischemic ulcer that could not be resolved with transmetatarsal amputation; previous treatment failure of inflow arteries (iliac, superficial femoral, and/or popliteal); former below knee bypass; significant stenosis or occlusion of inflow vessels tract (proximal disease) not successfully treated (<30% residual stenosis and without complication) prior to BTK angioplasty; and the target lesion nondilatable by balloon angioplasty. 
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Blood Institute classification system [15] . Within a treated lesion, if there were multiple post-PTA dissections, only the most severe dissection was reported. 
| Anti-platelet medication

| Study endpoints
The primary safety endpoint of this study was a composite of major adverse limb events (MALE) and peri-procedural death assessed at 1- determine degree of stenosis if present. An infrapopliteal stent study by Peregrin et al used similar measures of patency [16] . Primary patency was determined per patient and per vessel since multiple vessel treatment was permitted in the study. Primary patency was considered lost at the first occurrence of CD-TLR, major amputation or lack of an acceptable Doppler signal observed at the 1, 3, 6, or 12-month followup. In the per vessel analysis, CD-TLR and major amputation indicate lack of primary patency for all vessels within the patient. In the absence of CD-TLR and major amputation each vessel's patency is determined by whether a Doppler signal was audible at 30 days, 3, 6, and 12 months. Given no intervening CD-TLR or amputation, a missing Doppler evaluation could be determined to be patent given an audible signal present at a later follow-up.
Primary assisted patency was also assessed: if a vessel or patient lost patency but a revascularization occurred and the appropriate Doppler signal was present at subsequent visits, primary assisted patency was achieved.
| Statistical analysis
This was a first-in-human study for the use of Tack implants in BTK lesions and the primary intent of the analysis was to provide a 
| R E SU LTS
Thirty-five patients with 36 lesions were enrolled across six sites. Baseline patient and clinical characteristics are detailed in Table 2 . So as to not confound study results, patients were not treated with exercise therapy. Most patients were RC 5 (88.6%) with the remainder being Values are mean 6 SD or n (%). Values are mean 6 SD or n (%). RVD 5 reference vessel diameter; min 5 minutes; mm 5 millimeters; ml 5 milliliters. Changes in RC over time are displayed in Figure 6 . At baseline, 11.4% and 88.6% of patients had an RC scores of 4 and 5, respectively.
There was significant improvement in RC scores with 56.6% of the patients improving to RC class 0 or 1 at 6 months and 78.5% improving to RC class 0 or 1 at 12 months.
| D ISC USSION
The there were significant sustained clinical improvements in ABI and RC [14] .
Evaluations of strategies for revascularization of infrapopliteal lesions have indicated that the long-term patency is better in patients that receive tibial artery bypass when compared to PTA. Although the 12-month patency of infrapopliteal angioplasty is not as good as bypass (58.1 6 4.6% versus 81.5 6 2.0%; P < .05), the limb salvage rates are comparable (86.0 6 2.7% versus 88.5 6 2.2%; P > .05) [2, 3] . Interestingly, this long-term patency has not been shown to correspond to an improved rate of limb salvage as both PTA and bypass were shown to have similar rates [2, 3] . Given that limb salvage and reduced mortality are the desired outcomes in CLI associated with BTK disease, many treating physicians have opted to use PTA over bypass in this patient cohort. PTA has the advantage of better patient acceptance, lower health care utilization, and larger applicability when compared to bypass [4, 5] .
However, balloon angioplasty can have significant unfavorable effects to the vessel often resulting in dissection. The severity of dissection can range from mild disruptions of the vessel wall to severe flow limiting dissections [17] . The most common treatment for dissections is stenting. Stents are associated with failure, usually due to restenosis. Stent failure has been extensively studied in the femoropopliteal artery and many features of stents, including material, outward force, cell design, and strut thickness have been associated with poor outcomes [18] [19] [20] [21] [22] [23] [24] .
The Tack system, with its shorter length and open cell design, addresses some of the challenges with stents including restenosis, metal burden and fracture [9, [25] [26] [27] . In the previously published TOBA study, a mathematical model evaluation showed that metal burden was reduced by 81% by using Tacks to treat dissections when compared to stents [14] . In addition, the shorter length of Tacks should make them less susceptible to fracture, easier to cross for endovascular reintervention, and allow a placement location for a bypass graft reintervention. 
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Published data indicate that untreated post-PTA dissections, not just flow-limiting dissections, are associated with reduced patency. In one study, the 6-month TLR rate was 10.5% for patients without dissections and 33% and 44% for patients with grade A-B and C-E dissections, respectively [28] . Although post-PTA dissection is a well-known and widely reported feature of vascular intervention, accurate assessment of the severity and the clinical sequelae of dissections at the time of the procedure have proven difficult. In this clinical trial, all dissections were treated in an effort to reduce the negative consequences associated with untreated dissections. The predicate TOBA study data support the concept that treatment of femoropopliteal dissections has a beneficial effect on clinical outcomes [14] . In patients with CLI caused by infrapopliteal lesions, the Tack Endovascular System appears to be a feasible alternative to stenting post-PTA dissections.
| L I M I TA TI ONS
This study was conducted as a first-in-human evaluation of infrapopliteal lesions in a small number of patients. As such, it was a single arm study and there was no contemporary comparator group. This study, along with the previously published TOBA study in above the knee lesions, has shown the applicability of this treatment in patients with short lesions in two anatomic areas. The broad applicability of these results requires further studies. All patients were treated with nondrug 
